TWI251591B - Process for preparing discodermolide and analogues thereof - Google Patents
Process for preparing discodermolide and analogues thereof Download PDFInfo
- Publication number
- TWI251591B TWI251591B TW090118912A TW90118912A TWI251591B TW I251591 B TWI251591 B TW I251591B TW 090118912 A TW090118912 A TW 090118912A TW 90118912 A TW90118912 A TW 90118912A TW I251591 B TWI251591 B TW I251591B
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- formula
- alkyl
- patent application
- hydrogen
- Prior art date
Links
- AADVCYNFEREWOS-UHFFFAOYSA-N (+)-DDM Natural products C=CC=CC(C)C(OC(N)=O)C(C)C(O)C(C)CC(C)=CC(C)C(O)C(C)C=CC(O)CC1OC(=O)C(C)C(O)C1C AADVCYNFEREWOS-UHFFFAOYSA-N 0.000 title abstract 2
- AADVCYNFEREWOS-OBRABYBLSA-N Discodermolide Chemical compound C=C\C=C/[C@H](C)[C@H](OC(N)=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C/[C@H](C)[C@@H](O)[C@@H](C)\C=C/[C@@H](O)C[C@@H]1OC(=O)[C@H](C)[C@@H](O)[C@H]1C AADVCYNFEREWOS-OBRABYBLSA-N 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 44
- 238000000034 method Methods 0.000 claims abstract description 15
- 125000000217 alkyl group Chemical group 0.000 claims description 34
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 29
- 239000002253 acid Substances 0.000 claims description 19
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- 239000001257 hydrogen Substances 0.000 claims description 17
- 125000006239 protecting group Chemical group 0.000 claims description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 15
- -1 ketone compound Chemical class 0.000 claims description 15
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine group Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 7
- 239000003495 polar organic solvent Substances 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 230000008878 coupling Effects 0.000 claims description 6
- 238000010168 coupling process Methods 0.000 claims description 6
- 238000005859 coupling reaction Methods 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 238000010511 deprotection reaction Methods 0.000 claims description 3
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 2
- 230000032050 esterification Effects 0.000 claims description 2
- 238000005886 esterification reaction Methods 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 239000007789 gas Substances 0.000 claims description 2
- 239000003586 protic polar solvent Substances 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 4
- RHUYHJGZWVXEHW-UHFFFAOYSA-N 1,1-Dimethyhydrazine Chemical compound CN(C)N RHUYHJGZWVXEHW-UHFFFAOYSA-N 0.000 claims 2
- 150000000185 1,3-diols Chemical class 0.000 claims 2
- 239000000376 reactant Substances 0.000 claims 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 claims 1
- PUNXVEAWLAVABA-UHFFFAOYSA-N 1,2,3,4-tetrahydroanthracene;1,2,5,6-tetrahydroanthracene Chemical compound C1=CC=C2C=C(CCCC3)C3=CC2=C1.C1=CCCC2=C1C=C1CCC=CC1=C2 PUNXVEAWLAVABA-UHFFFAOYSA-N 0.000 claims 1
- 244000062793 Sorghum vulgare Species 0.000 claims 1
- PLZVEHJLHYMBBY-UHFFFAOYSA-N Tetradecylamine Chemical compound CCCCCCCCCCCCCCN PLZVEHJLHYMBBY-UHFFFAOYSA-N 0.000 claims 1
- XBDYBAVJXHJMNQ-UHFFFAOYSA-N Tetrahydroanthracene Natural products C1=CC=C2C=C(CCCC3)C3=CC2=C1 XBDYBAVJXHJMNQ-UHFFFAOYSA-N 0.000 claims 1
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 238000001354 calcination Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940125797 compound 12 Drugs 0.000 claims 1
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical group C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 claims 1
- 238000004945 emulsification Methods 0.000 claims 1
- 150000004820 halides Chemical class 0.000 claims 1
- 239000012433 hydrogen halide Substances 0.000 claims 1
- 229910000039 hydrogen halide Inorganic materials 0.000 claims 1
- RSHAOIXHUHAZPM-UHFFFAOYSA-N magnesium hydride Chemical compound [MgH2] RSHAOIXHUHAZPM-UHFFFAOYSA-N 0.000 claims 1
- 229910012375 magnesium hydride Inorganic materials 0.000 claims 1
- 235000019713 millet Nutrition 0.000 claims 1
- 239000007800 oxidant agent Substances 0.000 claims 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical class C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 claims 1
- 239000002798 polar solvent Substances 0.000 claims 1
- 239000011877 solvent mixture Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 4
- 238000003786 synthesis reaction Methods 0.000 abstract description 3
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 28
- 239000000203 mixture Substances 0.000 description 19
- 239000000243 solution Substances 0.000 description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- 235000019439 ethyl acetate Nutrition 0.000 description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 101150041968 CDC13 gene Proteins 0.000 description 7
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 102000029749 Microtubule Human genes 0.000 description 6
- 108091022875 Microtubule Proteins 0.000 description 6
- 102000004243 Tubulin Human genes 0.000 description 6
- 108090000704 Tubulin Proteins 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 210000004688 microtubule Anatomy 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L sodium sulphate Substances [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 235000016425 Arthrospira platensis Nutrition 0.000 description 2
- 240000002900 Arthrospira platensis Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 102220530780 Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 2_H24A_mutation Human genes 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000002923 oximes Chemical class 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 229940082787 spirulina Drugs 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- DIIIISSCIXVANO-UHFFFAOYSA-N 1,2-Dimethylhydrazine Chemical compound CNNC DIIIISSCIXVANO-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108010049959 Discoidins Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 102220467377 Insulin-like growth factor-binding protein 4_H15A_mutation Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000036815 beta tubulin Diseases 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- PBDGWRVFLZHMES-UHFFFAOYSA-N fluoroform hydrochloride Chemical compound Cl.FC(F)F PBDGWRVFLZHMES-UHFFFAOYSA-N 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000007273 lactonization reaction Methods 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 230000008880 microtubule cytoskeleton organization Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940023569 palmate Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide-pyridine complex Substances O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/30—Oxygen atoms, e.g. delta-lactones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Steroid Compounds (AREA)
- Pyrane Compounds (AREA)
Description
1251591 A7 ----- B7 五、發明説明(1 ) 本發明係關於用於製備盤皮海綿素及其類似物之方法, 利用於該方法中之新穎化合物及經由該方法所製備之新穎 化合物。 發明背景_
(+)-盤皮海綿素 装
•線 (+)-盤皮海綿素是經由研究人員在 Harbor Branch Oceanographic Institution (HBOI)自海中海綿盤皮海綿素 dissoluta的萃取物中所雜析之新穎聚克肽(p〇lyketide)天然 產物(Gunasekera SP,Gunasekera M, Longley RE,Schulte GK.盤 皮海綿素:來自海中海綿盤皮海綿素dissoluta之新穎生物 活性聚經基化之内g旨[published erratum出現在J. Org. Chem. 1991; 56:1346]· J. 〇rg· Chem· 1990; 55:4912-15 )。盤皮海綿素 缺少與派克泰索(paclitaxel)之顯然結構上相似性,但是它 與派克泰索(藥物Taxol中之活性物質)共有穩定化微管之 能力。在以機理爲基礎之分析中,盤皮海綿素較派克泰索 更爲有效。事實上,在熟知可引發純化之微管蛋白聚合之 少數化合物中,盤皮海綿素是最有效。然而,微管,細胞 中之主要結構組份不是微管蛋白的簡單平衡聚合物。彼等 本紙張尺度適用中國國家標準(CNS) A4規格(210 X 297公釐) 1251591 A7 B7 五、發明説明(2 ) 以α與β微管蛋白之雜二聚體的調節之GTP驅動動態組合 體而存在。雖然在分界面細胞中動力學是相當緩慢,但是 於進入有絲分裂時,生長和縮短之速率增加20至100倍 -每十秒鐘,平均微管轉變成半數的微管蛋白亞單位。此 種速率之改變容許細胞骨架之微管網絡解體及雙極梭形式 排列的微管組合。該梭附著至染色體而使彼等移動分開。 回應於細胞中微管動力學的完全抑制是死亡。然而,絲狀 分裂的細胞是較爲敏感而耐力低限似乎是細胞型特抗原分 子。像以高親和力連合至微管之派克泰索中斷具有致命結 果之腫瘤細胞中之動力學程序甚至當結合之藥物之微管蛋 白的比率是極低時。盤皮海綿素結合至微管蛋白與派克泰 索競爭。因爲派克泰索已證明於治療某些癌症時有效,所 以相同機理類別的其他化合物可具有對抗高增殖性疾病之 利用性。 盤皮海綿素或結構上相關之類似物的未來發展由於缺乏 可靠天然來源之化合物或可實行之合成路徑而受阻礙。天 然產生之盤皮海綿素甚至稀少且收獲產生之有機體構成邏 輯上之問題。因此,有不斷增加之須要改良式合成方法其 能製備商業上可接受數量的盤皮海綿素和結構上相關之類 似物。 發明概要 本發明係關於製備盤皮海綿素及其類似物之較爲實用之 合成法。在另外具體實施例中,本發明係關於使用以製備 盤皮海綿素及其類似物之新穎化合物。在更進一步具體實 本紙張尺度適用中國國家標準(CNS) Α4規格(210 X 297公釐)
.線 1251591
^2 A7 B7 五、發明説明(3 ) 施例中,本發明係關於經由本發明的方法所製備之新穎化 合物。 發明之詳述 本發明的要旨是發現用以製造盤皮海绵素及其類似物之 較爲實用之合成方法。較詳言之,頃發現:盤皮海绵素及 其類似物可經由三步驟反應予以製備如下: 步驟
β-羥基醛類偶合
本紙張尺度適用中國國家標準(CNS) Α4規格(210 X 297公釐)
1251591 A7 B7 五、發明説明(4 ) 步驟2 3
其中K是(C^)烷基,苄基或一個酸不穩定之羥基保護基 團;R2是(Cu)烷基或苄基;R3是氫,(Cu)烷基,芊基 CCCOCCbu)烷基、C(0)Ph、¢:(0)0((3^2)烷基、C(0)0Ph、 CCCONHCChJ烷基、C(0)NHPh或一個酸不穩定之羥基保 護基團;R3n是一個酸不穩定之羥基保護基團;R4是氫或 甲基;而X是〇,NH,NCH3,或S或CH2,其附帶條 件爲:當式I之化合物中,X是〇而R3是一個酸不穩定 之羥基保護基團時,式V之化合物中"-X-R3n部份是-0H。 本紙張尺度適用中國國家標準(CNS) A4規格(210 X 297公釐) 1251591 A7 B7 五、發明説明(5 ) 關於個別步驟,步驟1包括經由醛酵反應使式I之酮化 合物與式II之醛化合物偶合而獲得式III的β-羥基酮化合 物。該項偶合係相對於式Π之醛化合物,使用1與20 間,較佳是5與15間當量的式I之酮化合物而便利進 行。偶合係在負1〇〇 °C至20 Ό間之溫度下(較佳在負78 °C 至負20 °C )於有下列(1)至(3)項化合物存在下予以實施歷 2至72小時之一段時間,較佳歷16小時:1)二烷基硼鹵 化物或三氟·甲續酸鹽,較佳是對掌性氯化硼或三氟甲橫酸 鹽’更佳是β-氣'一異松4婦基棚燒;2) *種驗,較佳是* 種胺,更佳是三乙胺;及3) —種極性有機溶劑,較佳是一 種醚,更佳是二乙醚。 步驟2係關於還原式III的β-經基酮化合物,(較詳言之 是此等化合物共同之酮基團)而獲得式IV的i,3-二醇化合 物,邏原係在78 °C至20 °C間之溫度(較佳是負40 °C至負 10 °C)下,於有下列1)至3)項化合物存在下予以實施歷2 至72小時之一段時間,較佳歷16小時:1) 一種酮還原 劑,較佳是氫棚化物例如四甲銨三乙醯氧基氫硼化物;2) 一種極性有機溶劑,較佳是乙腈;及3) —種質子溶劑,較 佳是一種羧酸例如乙酸。 關於步驟.3 ,它包括將式IV化合物的酸不穩定之羥基 保護基團内酯化及去保護而獲得式V化合物。内酯化及去 保護反應係在負20 C至40 °C間之溫度(較佳自20 °C至25 °C )下’於有下列Ό和2)項之化合物存在下予以實施歷8 小時至7天的一段時間,較佳自16至72小時,更佳自24 -8 - 本紙張尺度適财S ®家料(CNS) A4規格(21GX 297公釐)'---- ---—
裝 訂
、線 1251591 A7 B7 五、發明説明(6 ) 至48小時:1) 一種質子酸,較佳是質子酸水溶液,較佳 是一種_化氫水溶液例如含水之氯化氫;2) —種極性有機 溶劑,較佳是極性有機溶劑之混合物,更佳是一種脂族醇 和一種醚之混合物,例如甲醇與四氫吱喃。 在另外具體實施例中,本發明係關於式I之新穎酮化合 物··
% ch3 CH; 其中 R!是(C^)烷基,芊基或一種酸不穩定之羥基保護 基團; R2是〇^_6)烷基或苄基: R3是氫,(Ck)烷基,苄基,¢:(0)((:^2)烷基, C(0)Ph,¢(0)0((3^2)燒基,C(0)0Ph,C(0)NH(C卜 12)烷基、C(0)NHPh,或是一種酸不穩定之羥基保 護基團; FU是氫或甲基;及 X 是 0,NH,NCH3,S 或 CH2。 較佳之化合物是式la的那些化合物:
(V ch3 ch: 本紙張尺度適用中國國家標準(CNS) A4規格(210X 297公釐) 1251591 A7 B7 五、發明説明(7 ) 其中 每一個I和R2是(Cm)烷基; X是0,或CH2 ;而 R3與R4係如上文中所界定。 更佳之化合物是式lb的那些化合物:
py ch3 ch. 其中 R,是(Ck)烷基,0(0)((^_12)烷基,芊基, 〇(0)0((^-12)烷基,或一種酸不穩定之羥基保護基 團;而
Ri·與R2’是如上文中所界定。 甚至更佳之化合物是式Ic的那些化合物:
CH3 ch3 ch: 其中 R3n是一個酸不穩定之羥基保護基團。 在上述各定義中:如本文所使用者,術語π (<^_6)烷基π 係關於僅由碳和氫所組成並具有自1至6個碳原子之直或 支鏈基團,而,如本文中所使_用者,術語”(Cm2)烷基”係 關於僅由碳和氫所組成並具有自1至12個碳原子之直或 支鏈基團。”燒基”基團的實例包括甲基、乙基、丙基、丁 基、戊基、3-甲基戊基等。 本紙張尺度適用中國國家標準(CNS) A4規格(210x 297公釐) 1251591 A7 B7 五、發明説明(8 ) 如本文中所使用者,術語”酸不穩定之羥基保護基團”係 關於於暴露至一種酸中時可被移除之任何氧結合基團。此 等基團的甚多實例爲熟諳該項技藝之人士所熟知且可在 1991 年紐約 John wiley & Sons 公司出版,Greene 和 Wuts, 有機合成中保護基團,第二版中見到。特定實例包括(但 不限於)第三-丁基二甲基矽烷基、三乙基矽烷基、第三-丁基二苯基矽烷基、三異丙基矽烷基、甲氧基甲基和四氫 口瓜喃基。. _ 在另外具體實施例中,本發明係關於用於製備式I之新 穎化合物之方法。較詳言之,式I之化合物可以如下所示 方式予以製備:
步驟A
步驟B
-11 - 本紙張尺度適用中國國家標準(CNS) A4規格(210X 297公釐) 1251591 A7 B7
1251591 A7 ___ ___B7 一__ 五、發明説明(10 ) 將一種反應的粗製產物不須純化而有利採用於下列反應 中 〇 如爲熟爾該項技藝之人士顯然可見,式I或ΙΙΙ>βΙν的化 合物含有不對稱碳原子而因此,應暸解··考慮將個別之立 體異構物包括在本發明的範圍以内。 下列實例僅係爲了舉例説明之目的,益無意欲以任何方 式限制本發明的範圍。 實例1 一 (2R,3S,4R)-3[[(i,i_二甲基乙基)二甲基矽虎基]氧基]_Ν_甲 氧基-Ν,2,4-三甲基_5_酮基-己醯胺 OMe
在〇 °c下,經由加成漏斗將15〇毫升之二甲亞砜中, 19.0克(120毫莫耳)之三氧化硫吡啶錯合物逐滴加至包括 150毫升之二氣曱烷、5〇毫升之二甲亞颯和25亳升之三 乙胺之混合物中的13.1克(39.5毫莫耳)之階段1.1中所製 備之非對映體混合物溶液中。然後在〇。(:下將所得之溶液 攪拌歷1.5小時,在此段時間後,將反應混合物在<1〇乇 下之冷卻浴中經由旋轉蒸發器而濃縮。然後將溶液用2〇〇 毫升之醚稀釋,然後用200毫升的1M硫酸氫鈉溶液和 200毫升之鹽水連續萃取。然後將有機層在Na2S〇4上乾 -13- 本紙張尺度適用中國國家標準(CNS) A4規格(210X 297公釐) 1251591 A7 ____B7 五、發明説明(11 ) '~ 燥,將粗製產物混合物經由急驟層析予以純化(起始採用 已烷作爲洗提液,然後採用已烷中5%乙酸乙酯的洗提液 混合物)而產生所需要之化合物係一種透明油。 lR NMR (300 MHz, CDC13)5 4.23 (dd3 J=7.5, 4.2 Hz, 2H)5 3.61 (s,3H),3.01 (s,3H),2.92 (m,2H),2.64 (m,2H),2.08 (s,3H), 1·〇3 (d,J-6·8 Hz,3H),0.98 (d,J=7.2 Hz,3H),0.81 (s,9H),0.00 (s,6H) 〇 1,1 :(汉,38,48)-3-!^1,1-二甲_基乙基)二甲基矽烷基] 氧基]-5-羥基-N-甲氧基-N,2,4-三甲基己醯胺 在負40 C下’將1〇·2毫升(30.5毫莫耳)的醚中之甲基 鎂化溴3M溶液逐滴加至50毫升醚中,6.9克(21.8毫莫 耳)的(2R,3S,4R)_3[[(1,1·二甲基乙基)二甲基矽烷基]氧基卜 N-甲氧基-N,2,4-二甲基-5-嗣基成醯胺溶液中,在加成後 將混合物在負20 °C下攪掉歷1小時。然後將反應混合物 用200毫升之醚稀釋及將反應經由添加反應混合物至2〇 克的0 °C下之碎冰中而驟冷。然後將混合物用100毫升之 1M硫酸氫鈉溶液洗滌並用兩個丨5〇毫升部份的醚分配。 然後將有機層合併在硫酸鈉上乾燥。然後將粗製產物混合 物層析(起始採用己烷中20%乙酸乙酯的洗提液混合物, 然後使用己烷中40%乙酸乙酯的洗提液混合物)而產生兩 種非對映立體異構物係淡黃色油,不須更進一步純化而使 用於下一步驟中。 對映立體異構物 1 : NMR (300 MHz, CDC13)5 4.08 (dd, J=9.8, 6.8 Hz,2H),3.64 (s,3H),3.54 (d,J=2.6 Hz,2H),3.08 (s, -14- i紙張用中國國家標準(CNS) A4^格(21〇 x 297公爱) 1251591 A7 _____ B7 五、發明説明(Π ) 3H),3.00 (m,2H),1,48 (m,2H) 1.07 (d,JT=6.8 Hz,3H),1.05 (d, 4 Hz,3H),0.81 (s,9H),0.76 (d,J=7.2 Hz,2H),0.01 (d,J=3.8
Hz,6H) 〇 映立體異構物 2 : 4 NMR (300 MHz,CDC13): δ 4·19 (dd, J=12.1,6·0 Hz,2H),3.86 (dd,J=9.0, 1.51 Hz,2H),3.56 (s,3H), 3.18 (m,2H),3.01 (s,3H),1.28 (m,2H),1.06 (d,J=6.8 Hz,3H), 0.94 (d,6.4 Hz,3H),0.88 (d,7.2 Hz,3H),0·78 (s,9H),0.01 (d, 13 Hz, 6H) 實例2 (2R,3S,4R,7S,8Z,10S,11S,12S,13Z,16S,17R,18R,19S,20S,21E)-19-[(胺基羰基)氧基]-3,11-17-叁[[(1,1-二甲基乙基)二甲基矽 燒基]氧基]-7-羥基-N-甲氧基-N,2,4,10,12,14,16,18,20-壬甲 基-5-酮基_8,13,21,23_廿四、四烯醯胺
將1·〇4毫升(11當量,在氫化鈣上蒸餾)之三乙胺,然 後3毫升之二乙醚中,2 25克(6 79毫莫耳,1〇當量)之 實例1化合物溶液加至4毫升之〇 I下的二乙醚中,2.18 克(6·79毫莫耳,10當量)的氯二異松莰烯基硼烷的 經攪拌溶液中。在〇下授摔歷2小時後,將混合物冷卻 -15- 本纸張尺度適财關家標準(CNS) 1251591 A7 B7 ________ 五、發明説明(I3 ) 至負78 °C,在此段時間後,將4毫升的二乙醚之450毫 克( 0.679 毫莫耳)的(2Z,4S,5S,6S,7Z,10S,11R,12R,13S,14S,15E) -13-[(胺基羰基)氧基]_5,11-雙[[(1,1-二甲基乙基)二甲基 矽烷基]氧基]-4,6,8,10,12,14-六曱基-2,7,15,17-十八四烯醛 的預冷卻(負7 8 °C )之溶液經由插管而添加在將所產生之 混合物維持在負78 °C的溫度歷3小時後,將它轉移至冷 凍器(負27 °C )歷16小時。然後將反應用8毫升之甲醇 (使用12毫升之缓衝劑溶液將其pH値調節至7 )和4毫升 的0 °C下之50%過氧化氫溶液驟冷。在25 °C下擾拌歷2 小時後,分離有機層。然後將水層用25毫升部份的二氯 甲烷萃取五次。然後將合併之有機層在MgS04上乾燥,使 用旋轉蒸發器予以濃縮並層析(Biotage,;?夕凝膠,梯度 至30%乙酸乙酯/己烷)而產生所需要之化合物係無色、高 黏滯油。 [a]D+12.56°(c=1.0, CH2C12); IR (CH2C12) 3547 (m,0H),3359 (m, C0NH2),2958 (vs),2990 (VS),1729 (vs,C=0),1664 (m), 1462 (s),
1385 (s), 1254 (s), 1037 (s), 1037 (s)? 1004 (s)? 835 (vs); NMR (500 MHz,CDCI3) δ 6.61 (1H,ddd,J=17.1,10.5,iq 5 hz H23) 6.03 (1H, dd,J—11.0, 11·0 Hz,H22),5.50 (1H, dd,J=i〇 6 10 6 Hz H9),5.37 (1H,dd,J-10.6,10.5 Hz, H21),5.35 (1H,dd,J=l〇.8 8 5 Hz,Hg),5.23 (1H,dd,J—15.3,2.1-Hz,H24A),5.13 (1H,d, J=10 2 Hz,H24B),5.05 (1H,d,J-10.0 Hz,H13),4.79 (1H,t,J=8 0 Hz H7)
4.72 (1H,t,J=5.9 Hz,H19),4.60-4.50 (2H,br,C〇NH£) 4 33 (1H dd, J=6.9, 4.3 Hz,H3),3.74 (3H,s,NOCE3),3.43 (1H,dd,J=5.0 -16 · 本紙張尺度適用中國國家標準(CNS) A4規格(210 x 297公釐) 一--- 裝 訂
*線 1251591 A7 B7 五、發明説明(14 ) 4.1 Hz,H17),3.31 (1H,dd,J=5.2, 5.1 Hz,Hu),3.13 (3H,s,NCH3), 3.08 (1H,br,OH),3.00 (1H,m,H2。),2.78-2.69 (2H,m,H4 +H6a), 2.70-2.62 (1H,m,H10),2·66-2·54 (2H, m,H2+H6B),2.49-2.45 (1H, m,H12),2.12 (1H, dd,J=12.4, 12.3 Hz,H15A),1.93-1.86 (2H,m, H16+H18),1.76-1.65 (1H,m,H15B),1.62 (3H,s,Me14),1.14 (3H, d,J=7.0 Hz,Me2),1.11 (3H,d,J=7.0 Hz,Me4),1.00 (3H,d,J=3.1 Hz, Me20),0·99 (3H,d,J=3.3 Hz,Me10),0.96-0.90 (21H,m, Meig+2xSiC(CH3)3), 0.88 (3H? d, J=6.6 Hz, Me^), 〇 83 (9H, s, SiC(CEs)3),0.73 (3H,d,J=6.7 Hz,Me16),0.10 & 0.08 & 0.04 & 0.03 & 0.03 & 0.01 (6x3H,3xSi(CH3)2); 13C NMR (100.6 MHz,CDC13) δ 212.9, 175.9, 156,9, 136.0, 133.7, 132.1,131,9,131.3,129.8,129.6,117.9,80.6,78.7,76.8,73.6, 64.9, 62.1,61.3, 54.7, 53.1,51.7, 49.0, 45.1,44.9, 37.9, 37.1,36.2, 35.9, 35.0, 34.4, 30.0, 29.1,26.26, 26.24, 25.97, 23.0, 18.51,18.5, 18.43, 18.14, 17.43, 16.44, 13.5, 10.99, 10.1,-3.29, -3.4, -3.5, -3.9, -4.1,-4.4; m/z (ESI+) 1017 (100 (MNa+))。 實例3 (2R,3S,4S,5S,7S,8Z,10S,11S,12S,13Z,16S,17R,18R,19S,20S,21E)-19-[(胺基羰基)氧基]-3,11-17-叁[[(1,1-二甲基乙基)二曱 基矽烷基]氧基]-5,7-二羥基-N-曱氧基-乂2,4,10,12,14,16,18,20-壬甲基-8_,13,21,23-廿四、四烯醯胺 -17- 本紙張尺度適用中國國家標準(CNS) A4規格(210X297公釐) 裝 訂
“線 1251591 A7 -------- B7 五、發明説明(1S )
中,將混合物在周圍溫度下攪摔歷30分鐘。然後將混合 物冷卻至負29 C,將1毫升之無水乙腈中之45〇毫克 (0.453笔莫耳)的實例2化合物之溶液加至冷卻之混合物 中。然後將所產生之混合物在負29。〇下攪拌歷18小時, 在此段時間後,將反應用2毫升之〇·5Ν含水之酒石酸鈉 钾驟冷。然後容許混合物緩慢溫至周圍溫度,在此段時間 後’將它用一鼠甲燒稀釋並用飽和之NaHC03洗條。然後 將水層用二氯甲烷萃取四次。然後將合併之有機層用鹽水 洗滌,使用硫酸鈉乾燥及在眞空中濃縮。然後將所產生之 殘渣經由急驟層析而純化(Biotage ,矽凝膠,梯度10-30% 乙酸乙酯/己烷)而產生所需要之化合物係白色固體。 [a]+29.75 degree (c=0.87? CH2C12); lR NMR (499.87 MHz, CDC13) δ 6.60 (1H,ddd,J=16.8, 10.5, 10.5 Hz,H23),6.02 (1H,t, J=11.0, H22),5·48 (1H,dd,J=10.0, 9.8 Hz,_H9),5·37 (1H,dd,J=l〇.6, 11.2 Hz,H21),5·35 (1H,dd,J=10.8, 8.5 Hz,H8),5.22 (1H,d,J=15.8, Hz,H24A), 5.12 (1H,d,J=10.2 Hz,H24B),4·98 (1H,d,J=l〇」Hz, H13),4.79 (1H,t,J=6.3 Hz,H7),4·65 (1H,t,J=5.9 Hz,H19),4.60· -18 - 本紙張尺度適用中國國家標準(CNS) A4規格(210 X 297公釐) 1251591 A7 B7 五、發明説明(l6 )
4.50 (2H,br,CONH^),4.20 (1H,dd,J=7.7, 2.3 Hz,H3),3.92 (1H, m,H5),3.73 (3H,s,NOCfib),3.45 (1H,br,OH-5),3.41 (1H,dd, J=10.9 4.7 Hz,H17),3.31 (1H,dd,J=5.2, 5.1 Hz,Hu),3.18 (3H,s, NCH3),3.08 (1H,br,OH),2.99 (1H,m,H20),2.67 (1H,m,H10), 2.43-2.41 (2H,m),2.11 (1H,t,J=12.3 Hz),1.90-1.87 (2H,m), 1.76-1.58 (10H,m),1.25 (3H,t,Me),1.17 (3H,d,J=7.1 Hz,Me), 0.99 (3H,d,J=6.4 Hz,Me),0·97 (3H,d,J=6.5 Hz,Me) 0.93-9.83 (30H,m,Me十3xSiC(CH3)3),0.71 (3¾ d,J=6.8 Hz,Me),0.10 & 0.08 & 0.04 & 0.03 & 0.03 & 0.01 (6x3H,3xSi(CEs)2)。 13C NMR (100.6 MHz,CDC13) δ 156.88,140.02,134.19,133.66, 132.10,131.88,131.40,131.30,131.11,130.06,129.79,117.91, 115.44,80.79,80.69,78.61,78.32,74.31,70.68, 65.55,61.66, 45.69,40.38,38.36,37.92,37.83,37.29, 36.29, 35.07, 34.91, 34.45,32.36,29.68,26.21,26.12,26.03,25.95,22.95,18.52, 18.43, 18.12, 17.41,17.07, 16.57, 13.44, 12.29, 10.32, 10.14, -3.20, -3.43, -3.96, -4.16, -4.48。m/z (ESI+) 1019 (100 (MNa+))。 實例4 製備(+)-盤皮海綿素 將56晕升的4N氫氣酸之水溶液加至56毫升的四氫吱 喃中450毫克(0.452毫莫耳)的實例3化合物溶液中。然後 將所產生之溶液在室溫下攪拌歷24小時,然後添加10毫 升之甲醇,然後將此溶液在室溫下攪拌歷另外24小時。 然後將50亳升之乙酸乙酯加至此溶液中,接著添加在0 °C時之NaHC〇3至pH値爲8 。然後將有機溶液用鹽水洗 -19- 本紙張尺度適用中國國家標準(CNS) A4規格(21〇X297公釐) 裝 訂
-線 1251591 A7 B7 五、發明説明(Π ) 滌。然後將水層用30毫升部份的乙酸酯萃取三次,將合 併之萃取物在Na2S04上乾燥。過濾及濃縮接著急驟層析 (起始採用乙酸乙酯中50%二氯甲烷的洗提液混合物,然 後採用100%乙酸乙酯產生(+)-盤皮海綿素。 [a]+22.0°(c=1.41,MeOH);熔點 122-124 °C ; 13C NMR (100.6 MHz,CDC13) δ 176.8,160.33,134.17,133.92,133.88,133.59, 133.28, 131.59, 13L00, 118.80, 80.66, 80.22, 78.48, 76.48, 73.66, 63.70,44.56,42.60,38.79,37.71,36..92, 36.77,36.69,34.97, 34.62,23.45,19.73,18.25,18.11,16.05,15.84, 13.27,9.44.m/z (ESI+) 594 (100 (M+1+)) 〇 -20- 本紙張尺度適用中國國家標準(CNS) A4規格(210 x 297公釐)
Claims (1)
1251 18912號專利申請案 中文申請專利範圍替換本(94年12月) 8 8 8 8 A B c D
| i粟, yrtlv.v*
、申請專利範圍 1. 一種用於製備式V之化合物之方法 OH
V 該方法包括:在第一步驟中,於有一種二烷基硼鹵化 物或三氣曱續酸鹽/_,一種胺驗和一種極性有機溶劑 之存在下,使式I的酮化合物:
與式II的醛化合物偶合 OFV
而獲得式III的β-控基嗣· 72298-941202.DOC 本紙張尺度適用中國國家標準(CNS) A4規格(210 X 297公釐). A B c D 1251591 六、申請專利範圍
在第二步驟中,經由在一種極性有機溶劑和一種質子 溶劑中使用一種氫硼化物反應物處理它而還原第一步 驟中所獲得之酮化合物,獲得式IV之1,3-二醇: /R1
及,在第三步驟中,經由用經溶入一種極性溶劑或溶 劑混合物中之鹵化氫處理它.,將第二步驟中所獲得之 1,3-二醇的酸不穩定羥基保護基團内酯化和脫去保護而 獲得所需要之式V化合物,其中R!是烷基、芊 基或酸不穩定之說基保護基團;R2是(C!_6)烧基或爷 基;R3是氫,(<^_6)烷基,苄基(:(0)((3^2)烷基、 C(0)Ph、¢:(0)0((:^2)烷基、C(0)0Ph、C^CONHCCbn)烷 基、C(0)NHPh或酸不穩定之羥基保護基團;R3”是酸 不穩定之羥基保護基團;R4是氫或甲基;而X是〇, 其附帶條件為:當在式I之化合物中,X是0而R3是 酸不穩定之羥基保護基團時,式V之化合物中之 R3”部份是-0H。 72298-941202.DOC >2- 本紙張尺度適用中國國家標準(CNS) A4規格(210 X 297公釐) 、申請專利範園 2·如申請專利範圍第1項之 78°C至負2〇。(:間之溫度下法,*中偶合步驟係在負 烷、三乙胺和二乙鍵的存在 4氣二異松获歸基爛 3·如申請專利範圍第丨項之、于从進行。 40t至負1〇t間之溫度;方其中還原步驟係在負 化物-乙腈和乙酸 :四甲叙二乙醯氧基爛氫 、仔在下予以推 4.如申請專利範圍帛i項 。 保護基團的内S旨化和 中酸不穩定之羥基 溫度下,於含水之备蔓係在負20°c至40°C間之 予以進行。 :化風、甲醇和四氫吱味之存在下 5· —種式I化合物,
其中 &是(c】.6)烷基; &是(c].6)烷基; R3是氫或C ! _ 6烷基矽烷基; R4是氫或甲基;而 X是0 〇 6·如申請專利範圍第5項之式I化合物,其係為式j b 72298-941202.DOC 本紙張尺度適用中國國家標準(CNS) A4規格(210X 297公釐) 8 8 8 8 A BCD 1251591 六、申請專利範圍
其中 R31是((2^6)炫基石夕烧基;而 RV和r2,係(Cu)烷基。 7·如申請專利範圍第6項之式I化合物,其係為式Ic
其中 R3”是(c^)烷基矽烷基。 8·如申請專利範圍第7項之化合物,其係具有下式之 (2R,3S,4R)-3[[(1,1-二甲棊乙基)二甲基矽烷基]氧基卜 曱乳基-Ν,2,4·三甲基-5- g同基-己酿胺 CH3 H3C\ 丨 π 0 0 Q N— H3C
CK 9· 一種用於製備如申請專利範圍第5項之式j化合物之 方法’該方法包括,在第一步驟中,於一種極性有機 存在下,添加甲4基或乙基有機金屬反應物至式
/«3
申請專利範 VI之酸中
/ ^ T 備之 R〗、 種氧化劑和-種驗處理它來氧化第Ί洛劑中使 醇化合物而+ 軋化弟—步驟中所製 物而獲侍所需要之式J化合物 3、R4和X係如申請專利範圍f 所、I、 負 10. 如申請專利範圍第9項之方法,“斤又義者。 之存 78t至,c間之溫度下,於甲心:加步驟係在 在下予以進行。 "鎂化涘和二乙醚 負 11. 如申請專利範圍第9項之方法,I 7rC至40t間之溫度τ, :中乳化步驟係在 三乙胺和二氯f貌之存在下予以進^厂咐口定錯合物 12· —種式III化合物, 7 72298-941202.DOC -5- 8 8 8 8 A BCD 1251591 六、申請專利範圍
其中 R!是((^_6)烷基; R2是(Cu)烷基; R3是氫或Ci_6烧基碎烧基; r4是氫或甲基; X是0 ;而 每一個R3”是三-(Cw)烷基矽烷基。 13.如申請專利範圍第12項之化合物,其係具有下式之 (2R53S54R,7S58Z510S,11S512S513Z516S517R,18R,19S520S521E) •19-[(胺基羰基)氧基]-3,11-17-叁[[(1,1·二甲基乙基) 二甲基矽烷基]氧基]-7-羥基-Ν-曱氧基-Ν,2,4510512,14,16518520-壬曱基-5-酮基-8513,21,23-廿四、 四烯醯胺
14. 一種式IV之化合物, 72298-941202.DOC 本紙張尺度適用中國國家標準(CNS) A4規格(210χ 297公釐) 8 8 8 8 A B c D 1251591 六、申請專利範圍 /R1
其中 R!是((^_6)烷基; R2是(Cu)烷基; R3是氫或Cl.6院基碎烧基; R4是氫或甲基; X是0 ;而 每一個R3”是三-(Cw)烷基矽烷基。 15.如申請專利範圍第1 4項之化合物,其係具有下式之 (2R,3S,4S55S57S,8Z,10S,11S,12S,13Z,16S,17R,18R519S,20S52 1E)-19-[(胺基羰基)氧基]-3,11,17-參[[(1,1-二甲基乙基) 二曱基石夕烷基]氧基]·5,7-二羥基-N-曱氧基-队2,4,10,12,14,16,18,20-壬曱基-8,13,21,23-廿四、四烯醯 胺
72298-941202.DOC - 7 - 本紙張尺度適用中國國家標準(CNS) Α4規格(210X 297公釐)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63375300A | 2000-08-07 | 2000-08-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
TWI251591B true TWI251591B (en) | 2006-03-21 |
Family
ID=24540984
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW090118912A TWI251591B (en) | 2000-08-07 | 2001-08-02 | Process for preparing discodermolide and analogues thereof |
Country Status (30)
Country | Link |
---|---|
EP (1) | EP1309583B1 (zh) |
JP (1) | JP2004505963A (zh) |
KR (1) | KR100796396B1 (zh) |
CN (1) | CN1293067C (zh) |
AR (1) | AR032761A1 (zh) |
AT (1) | ATE330948T1 (zh) |
AU (2) | AU9372601A (zh) |
BR (1) | BR0112876A (zh) |
CA (1) | CA2416769C (zh) |
CY (1) | CY1105338T1 (zh) |
CZ (1) | CZ300855B6 (zh) |
DE (1) | DE60120991T2 (zh) |
DK (1) | DK1309583T3 (zh) |
EC (1) | ECSP034459A (zh) |
ES (1) | ES2266266T3 (zh) |
HK (1) | HK1055962A1 (zh) |
HU (1) | HUP0300742A3 (zh) |
IL (2) | IL154109A0 (zh) |
MX (1) | MXPA03001192A (zh) |
MY (1) | MY127609A (zh) |
NO (1) | NO328365B1 (zh) |
NZ (1) | NZ523999A (zh) |
PE (1) | PE20020263A1 (zh) |
PL (1) | PL358839A1 (zh) |
PT (1) | PT1309583E (zh) |
RU (1) | RU2283309C2 (zh) |
SK (1) | SK1562003A3 (zh) |
TW (1) | TWI251591B (zh) |
WO (1) | WO2002012220A2 (zh) |
ZA (1) | ZA200300590B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004009574A1 (en) * | 2002-07-22 | 2004-01-29 | Novartis Ag | Synthesis of discodermolide |
US7321046B2 (en) | 2002-09-06 | 2008-01-22 | University Of Pittsburgh | Analogs of dictyostatin, intermediates therefor and methods of synthesis thereof |
US7122686B2 (en) | 2002-09-06 | 2006-10-17 | University Of Pittsburgh | Analogs of discodermolide and dictyostatin-1, intermediates therefor and methods of synthesis thereof |
US7214708B2 (en) | 2004-11-18 | 2007-05-08 | Kosan Biosciences Incorporated | Synthetic discodermolide analogs |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4939168A (en) * | 1989-08-11 | 1990-07-03 | Harbor Branch Oceanographics Institution, Inc. | Discodermolide compounds, compositions containing same and methods of preparation and use |
GB9315802D0 (en) * | 1993-07-30 | 1993-09-15 | Roussel Lab Ltd | Chemical compounds |
US5789605A (en) * | 1996-12-03 | 1998-08-04 | Trustees Of The University Of Pennsylvania | Synthetic techniques and intermediates for polyhydroxy, dienyl lactones and mimics thereof |
US6096904A (en) * | 1996-12-03 | 2000-08-01 | The Trustees Of The University Of Pennsylvania | Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives |
AU7267298A (en) * | 1997-04-30 | 1998-11-24 | Regents Of The University Of California, The | Synthesis of discodermolide and analogs |
GB0101599D0 (en) * | 2001-01-22 | 2001-03-07 | Novartis Ag | Organic compounds |
-
2001
- 2001-08-02 TW TW090118912A patent/TWI251591B/zh not_active IP Right Cessation
- 2001-08-02 MY MYPI20013637A patent/MY127609A/en unknown
- 2001-08-03 PE PE2001000777A patent/PE20020263A1/es not_active Application Discontinuation
- 2001-08-03 AR ARP010103736A patent/AR032761A1/es active IP Right Grant
- 2001-08-06 IL IL15410901A patent/IL154109A0/xx unknown
- 2001-08-06 AT AT01974118T patent/ATE330948T1/de not_active IP Right Cessation
- 2001-08-06 NZ NZ523999A patent/NZ523999A/en unknown
- 2001-08-06 CN CNB018137679A patent/CN1293067C/zh not_active Expired - Fee Related
- 2001-08-06 PT PT01974118T patent/PT1309583E/pt unknown
- 2001-08-06 HU HU0300742A patent/HUP0300742A3/hu unknown
- 2001-08-06 JP JP2002518197A patent/JP2004505963A/ja active Pending
- 2001-08-06 RU RU2003105816/04A patent/RU2283309C2/ru not_active IP Right Cessation
- 2001-08-06 BR BR0112876-0A patent/BR0112876A/pt not_active IP Right Cessation
- 2001-08-06 KR KR1020037001704A patent/KR100796396B1/ko not_active IP Right Cessation
- 2001-08-06 AU AU9372601A patent/AU9372601A/xx active Pending
- 2001-08-06 PL PL01358839A patent/PL358839A1/xx not_active Application Discontinuation
- 2001-08-06 WO PCT/EP2001/009068 patent/WO2002012220A2/en active IP Right Grant
- 2001-08-06 DE DE60120991T patent/DE60120991T2/de not_active Expired - Lifetime
- 2001-08-06 ES ES01974118T patent/ES2266266T3/es not_active Expired - Lifetime
- 2001-08-06 DK DK01974118T patent/DK1309583T3/da active
- 2001-08-06 CZ CZ20030330A patent/CZ300855B6/cs not_active IP Right Cessation
- 2001-08-06 MX MXPA03001192A patent/MXPA03001192A/es active IP Right Grant
- 2001-08-06 AU AU2001293726A patent/AU2001293726B2/en not_active Ceased
- 2001-08-06 CA CA002416769A patent/CA2416769C/en not_active Expired - Fee Related
- 2001-08-06 SK SK156-2003A patent/SK1562003A3/sk unknown
- 2001-08-06 EP EP01974118A patent/EP1309583B1/en not_active Expired - Lifetime
-
2003
- 2003-01-22 ZA ZA200300590A patent/ZA200300590B/en unknown
- 2003-01-23 IL IL154109A patent/IL154109A/en not_active IP Right Cessation
- 2003-01-31 EC EC2003004459A patent/ECSP034459A/es unknown
- 2003-02-06 NO NO20030587A patent/NO328365B1/no not_active IP Right Cessation
- 2003-11-13 HK HK03108266A patent/HK1055962A1/xx not_active IP Right Cessation
-
2006
- 2006-09-07 CY CY20061101284T patent/CY1105338T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HU225294B1 (en) | Oxazoline derivatives for synthesis of sidechain-bearing taxanes and preparation thereof | |
WO1989012632A1 (en) | Method of preparing sphingosine derivatives and an aldehyde used therein | |
JP6584696B2 (ja) | 3−((2s,5s)−4−メチレン−5−(3−オキソプロピル)テトラヒドロフラン−2−イル)プロパノール誘導体の製造方法及びそのための中間体 | |
TWI251591B (en) | Process for preparing discodermolide and analogues thereof | |
ES2325266T3 (es) | Sintesis de prostaglandina. | |
WO1993004038A1 (fr) | PROCEDE DE PREPARATION DE DERIVES DE LA β-PHENYLISOSERINE ET LEUR UTILISATION | |
JP3453188B2 (ja) | オレアノール酸誘導体の製造方法 | |
EP4130020A1 (en) | Novel method for preparing inotodiol | |
US6506910B1 (en) | Process for preparing discodermolide and analogues thereof | |
JP2000256244A (ja) | 4−メチルテトラフルオロベンジルアルコール誘導体の製造法 | |
AU2001293726A1 (en) | Process for preparing discodermolide and analogues thereof | |
JP3726996B2 (ja) | サイトキサゾンの合成方法 | |
JP4157175B2 (ja) | 2′−ピロリジンプロパン酸誘導体の製造方法 | |
JP3682291B2 (ja) | オレアノール酸誘導体の製造方法 | |
CN117142996A (zh) | 单胺基抑制剂类中间体及其合成方法与应用 | |
KR100503022B1 (ko) | 심바스타틴의 신규 제조방법 및 그에 사용되는 합성 중간체 | |
CN114656369A (zh) | 一种高烯丙胺类化合物、合成方法及其应用 | |
KR20220011502A (ko) | 신규한 이노토디올의 제조방법 | |
AU649251B2 (en) | Process for the preparation of 10-(2-propynyl)estr-4-ene-3, 17-dione | |
JPH08134047A (ja) | 光学活性5員環化合物及びその製造方法 | |
JPH061761A (ja) | γ,δ−不飽和−β−アミノ酸誘導体及びその製造方法 | |
JPH10265420A (ja) | シクロヘキシリデン誘導体の製造方法 | |
KR20100083213A (ko) | 스핀고신의 제조방법 | |
FR2541283A1 (fr) | Procede de preparation de (acyloxy-2 alkylthio-1 propyl) phosphorylcholine | |
JPS62242695A (ja) | 23,25,26−トリヒドロキシコレスタ−5−エン類の製造法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |